Best AI Tools for Radiologists in 2026

Interventional teams at some hospitals get a stroke alert on their phone before the radiologist has opened the study. That is the real change AI brought to radiology: not better diagnosis, but earlier notification. Most tools sold as diagnostic AI are triage systems wearing diagnostic clothing, and knowing which is which will save you a lot of procurement grief.

I've grouped these by what they do to your working day rather than by vendor category. If you want the broader clinical picture, our full list for doctors covers the documentation and decision-support side in more depth.

Quick comparison

Six of the seven are enterprise-only. Radiology AI gets sold to health systems, not to radiologists. If you read for a small imaging group, your practical options narrow to Glass Health and whatever your PACS vendor already bundles. That is a procurement reality nobody puts in the marketing copy.

Triage: Aidoc and Viz.ai

These two get grouped together constantly and they solve different halves of the same problem.

Aidoc analyzes studies as they land, flags critical findings (intracranial hemorrhage, pulmonary embolism, fracture), then pushes those cases up your worklist. It integrates into the radiology workflow rather than sitting in a separate viewer, which matters more than any accuracy figure. A tool that requires a second login gets abandoned in week three.

Viz.ai works one step further out. It analyzes the scan and then alerts the care team directly, so the neurointerventionalist and the radiologist find out at the same time. For stroke and large-vessel occlusion, that parallel notification is the entire value proposition. The radiologist still reads the study; the difference is that the cath lab started spinning up during the read instead of after it.

Which one you want depends on whether your bottleneck is reading order or downstream mobilization. Hospitals with a strong stroke program and a slow paging chain get more out of Viz.ai. Departments drowning in an undifferentiated worklist get more out of Aidoc.

Neither replaces a read. Both are explicitly triage and notification products, and vendors who let you believe otherwise are doing you a disservice.

Qure AI

Qure AI covers a wider modality spread than the two above, spanning chest X-ray and CT, with published work across TB screening and breast imaging. The company cites 90% sensitivity in breast cancer detection for its imaging models. Treat any single vendor-stated sensitivity number as a starting point for your own validation rather than a settled fact; sensitivity means very little without the matched specificity and the population it was measured on.

Where Qure AI earns its place is in high-volume screening settings, especially outside well-resourced systems. Chest X-ray triage in a setting with a large backlog and a thin radiologist bench is a genuinely different problem than worklist reordering in a US academic center, and Qure has more deployment history in the former than most competitors.

River Medical AI for mammography

Mammography is the one area where the second-reader framing is honest rather than marketing. River Medical AI flags suspicious findings on mammograms to assist with early breast cancer detection, positioned around reducing false negatives.

Double reading already has decades of evidence behind it in European screening programs. Slotting a model into that second slot is a smaller conceptual leap than most radiology AI asks you to make, which is why mammography AI has moved faster into routine use than, say, general CT interpretation.

The catch is calibration drift. A model tuned on one population's density distribution and one vendor's detector will behave differently on yours. Ask for the local validation cohort before you ask about the headline numbers.

Reporting and chart-side tools

Regard sits outside the imaging pipeline. It reviews patient data and surfaces diagnoses that may have been missed, aimed at reducing diagnostic error and cleaning up clinical documentation. For radiologists it matters indirectly: better structured problem lists upstream mean better clinical context on the requisition, which is the single most common complaint I hear from readers.

Tempus AI is oncology-focused, matching molecular and clinical data to identify treatment options and trial eligibility. If you read oncologic imaging, it changes the questions being asked of your reports more than it changes how you produce them.

Glass Health is the outlier and the only one a working radiologist can just sign up for. It generates differential diagnoses and clinical plans from patient data, with a free tier and Pro at $15/month. It is a reasoning aid, not an imaging tool. I include it because it is the only entry here that a single physician can evaluate this afternoon without involving a procurement committee.

Where the evidence is strong and where it thins out

Radiology AI gets discussed as one category. It isn't, and the quality of evidence behind it varies enormously by task.

Strongest: large-vessel occlusion and intracranial hemorrhage detection on CT. Binary, time-critical, visually distinctive, and with a clear downstream action that makes the benefit measurable. When people cite radiology AI success stories, they are almost always citing this.

Strong: mammography screening. Decades of double-reading evidence give a clean slot for a model, and screening populations are large enough to power real studies.

Middling: chest X-ray. High volume and plenty of models, but the findings are more varied and the clinical action less immediate, so measured benefit depends heavily on the setting. It performs best where the alternative is a long delay rather than a prompt human read.

Thin: general CT and MRI interpretation across arbitrary findings. This is the thing everyone imagined AI would do, and it remains the least solved. Models handle narrow findings well and generalize badly.

The practical takeaway is to distrust any pitch that treats these as one capability. A vendor with excellent LVO numbers has told you nothing about how their product performs on incidental findings in an abdominal CT.

The integration cost nobody quotes

The license is rarely the expensive part. Getting a tool into the PACS workflow means involving your imaging informatics team, your IT security review, and usually the PACS vendor, whose cooperation ranges from helpful to obstructive depending on whether they sell a competing module.

Budget realistically for that and for the ongoing maintenance. Every PACS upgrade risks breaking the integration, and someone has to own re-testing it. Departments that treat AI procurement as a software purchase rather than an integration project are the ones with expensive shelfware two years later.

Ask the vendor for reference customers on your specific PACS version. Not their marquee customer, one running your stack.

What none of these do

They don't reduce your read volume. Triage tools reorder work; they don't remove it. Several health systems have found that flagging more findings creates more downstream follow-up, not less.

They don't take liability. The signing radiologist owns the report. Every vendor on this list is explicit about this in their documentation, and any sales conversation that gets vague on the point should worry you.

They don't work well without integration budget. The single most reliable predictor of whether radiology AI gets used a year after purchase is whether it appears inside the existing PACS workflow or beside it. Budget for the integration, not just the license.

How to evaluate one of these

Ask for the local validation cohort, not the published one. Ask what happens to the flag when the model is wrong and who reviews those cases. Ask how the tool behaves during a PACS outage. And ask your technologists, because they will be the ones absorbing whatever new step the deployment adds.

If you're building a shortlist, start from your actual bottleneck. Departments that buy radiology AI because a competitor announced a partnership end up with a tool nobody opens.

FAQ

Does AI reduce radiologist workload? Not in the way the marketing suggests. Triage tools change the order of your worklist and speed up downstream teams. Studies flagged as critical still need a full read, and increased detection often generates additional follow-up imaging.

Are these tools FDA cleared? Clearance varies by product, by specific indication, and by market. A vendor may hold clearance for one finding on one modality and not others. Always confirm the clearance covers the exact indication you plan to use it for rather than the product name.

Can a small imaging group use any of these? Realistically, Glass Health is the only entry here with self-serve pricing at $15/month for Pro. The imaging tools are sold as enterprise licenses to hospitals and imaging centers, so smaller groups usually access them through a PACS vendor bundle.

What about the radiologist shortage argument? It is the most honest case for these tools and the most oversold. Triage genuinely helps when the backlog is large and the bench is thin, which is why deployment history in screening-heavy, resource-constrained settings is more informative than a demo on a curated dataset.

Should the model's flag go in the report? Practice varies and your institution should set a policy before deployment rather than after. Document whether an AI flag informed the read, because retrospective ambiguity about that question is where the medico-legal problems start.